Profile for Lifevantage Corporation (LXRX)
« Back to company indexLXRX Chatter Timeline
Stock Ticker for LXRX
Most Active Tweeters for LXRX
| User | Tweets |
|---|---|
| @traderal1 | 5 |
| @ThisLincolnian | 5 |
| @dispatchtribune | 4 |
| @ZolmaxNews | 3 |
| @1MinuteStock | 3 |
Recent Tweets for LXRX
 |
@InsiderAlertsIA $LXRX: New Insider Filing on EVP and CCO ALEXANDER A SANTINI: https://t.co/QaoIihrnnt May 25th 2018, 4:05pm |
 |
@ZolmaxNews Lexicon Pharmaceuticals $LXRX Earns “Outperform” Rating from Wedbush https://t.co/3MkjGEWaII May 25th 2018, 12:05pm |
 |
@tymorapro $LXRX: At 1DyHIGH=9.70, hits:2, ch:+3.1%, 7phNewHi:BrkPLo[+3.5%], 17:3Accel+, tf:1011111, medFlt:43M, HiPctSht[30%:… https://t.co/E9IKgnphZJ May 25th 2018, 11:05am |
 |
@registrarjourn Lexicon Pharmaceuticals $LXRX Earns “Outperform” Rating from Wedbush https://t.co/0SmJ9izhlJ May 25th 2018, 8:05am |
 |
@lisagillis_ RT @ChartMill: $LXRX: The short term trend is positive, while the long term trend is neutral. So this is evolving in the right ... https://… May 24th 2018, 7:05pm |
 |
@ChartMill $LXRX: The short term trend is positive, while the long term trend is neutral. So this is evolving in the right ...… https://t.co/gbKtE836pC May 24th 2018, 7:05pm |
 |
@ThisLincolnian Analysts Anticipate Lexicon Pharmaceuticals, Inc. $LXRX Will Post Earnings of -$0.35 Per Share https://t.co/VcZznzqigP May 24th 2018, 3:05pm |
 |
@ConsumerFeed Analysts Anticipate Lexicon Pharmaceuticals, Inc. $LXRX Will Post Earnings of -$0.35 Per Share https://t.co/hTExU0L2fm May 24th 2018, 3:05pm |
 |
@MrCDanso Lexicon Pharmaceuticals to Present at Upcoming Investor Conference $LXRX https://t.co/0ol6ZzF6Kt May 24th 2018, 7:05am |
 |
@GNWLive Lexicon Pharmaceuticals to Present at Upcoming Investor Conference $LXRX https://t.co/5PAMuNrMa8 May 24th 2018, 7:05am |
 |
@SolarMelt $LXRX Rolling over. Negative MACD Crossover pending - should take a couple of days. Sentiment coming down fast brin… https://t.co/jTMB8fOTq1 May 24th 2018, 1:05am |
 |
@fda_tracker $LXRX New PDUFA Date 2019-03-22 Lexicon Pharmaceuticals, Inc. Link:https://t.co/chfnrZCLdB Calendar:https://t.co/sCt1qKoMdr May 23rd 2018, 9:05am |
 |
@OlympiaReport Lexicon Pharmaceuticals $LXRX Given Outperform Rating at Wedbush https://t.co/H8uopOJt5q May 23rd 2018, 5:05am |
 |
@dispatchtribune Lexicon Pharmaceuticals $LXRX Given Outperform Rating at Wedbush https://t.co/CCvuTa0s3C May 23rd 2018, 5:05am |
 |
@traderal1 RT @Biotech_DD: $LXRX ??no cap raise overhang, cash sufficient to fund optations until cash flow positive ?? superior data set / v benign… May 22nd 2018, 11:05pm |
|
@traderal1 RT @ThisLincolnian: Lexicon Pharmaceuticals’ $LXRX Outperform Rating Reaffirmed at Wedbush https://t.co/tBPeOn8Yan May 22nd 2018, 11:05pm |
|
@traderal1 RT @StaticTrades: $LXRX FDA to review Zynquista (sotagliflozin) as potential treatment for type 1 diabetes May 22nd 2018, 11:05pm |
|
@traderal1 RT @WatchlistN: Lexicon Pharmaceuticals’ $LXRX Outperform Rating Reaffirmed at Wedbush https://t.co/j6fCY1UI3H May 22nd 2018, 11:05pm |
 |
@AmericanBanking Lexicon Pharmaceuticals’ $LXRX Outperform Rating Reaffirmed at Wedbush https://t.co/a68SyL55Gj #stocks May 22nd 2018, 5:05pm |
 |
@WatchlistN Lexicon Pharmaceuticals’ $LXRX Outperform Rating Reaffirmed at Wedbush https://t.co/j6fCY1UI3H May 22nd 2018, 5:05pm |
|
@ThisLincolnian Lexicon Pharmaceuticals’ $LXRX Outperform Rating Reaffirmed at Wedbush https://t.co/tBPeOn8Yan May 22nd 2018, 5:05pm |
|
@traderal1 RT @EEthougths: *LEXICON PHARMA RISES; GETS NEW STREET HIGH PT $42 AT WEDBUSH $LXRX May 22nd 2018, 4:05pm |
 |
@TheGoodKillers $LXRX wedbush, here's the brilliance of that shop https://t.co/6PSiQHI4fx May 22nd 2018, 2:05pm |
 |
@EEthougths *LEXICON PHARMA RISES; GETS NEW STREET HIGH PT $42 AT WEDBUSH $LXRX May 22nd 2018, 2:05pm |
|
@tymorapro $LXRX: [10alerts] At 1DyHIGH=10.07, hits:2, ch:+2.2%, 0NewHi+:BrkPLo[+3.7%], 1mMv:+3, 3:1Accel+, tf:1000001, FirmTr… https://t.co/WOrz4xcZhI May 22nd 2018, 2:05pm |
 |
@StaticTrades $LXRX FDA to review Zynquista (sotagliflozin) as potential treatment for type 1 diabetes May 22nd 2018, 8:05am |
 |
@stefanomjr $LXRX Lexicon Pharma, Sanofi $SNY Announce FDA to Review Zynquista as Potential Treatment for Type 1 Diabetes https://t.co/vcNr5Q6GeU May 22nd 2018, 8:05am |
 |
@StockTexts $LXRX $SNY FDA to review Zynquista™ (sotagliflozin) as potential treatment for type 1 diabetes Nasdaq:LXRX https://t.co/OCLJVoi9QI May 22nd 2018, 8:05am |
 |
@stockelite $LXRX FDA to review Zynquista™ (sotagliflozin) as potential treatment for type 1 diabetes https://t.co/ow3s0zOXIL May 22nd 2018, 8:05am |
|
@ConsumerFeed Lexicon Pharmaceuticals $LXRX Upgraded at BidaskClub https://t.co/J4XAJ7JDCr May 21st 2018, 3:05am |
 |
@dailypoliticaln Lexicon Pharmaceuticals $LXRX Raised to “Buy” at BidaskClub https://t.co/8TjpwxGo1w May 20th 2018, 1:05pm |
|
@dailypoliticaln Lexicon Pharmaceuticals $LXRX Raised to “Buy” at BidaskClub https://t.co/FTX45g5NAT May 20th 2018, 1:05pm |
|
@dailypoliticaln Lexicon Pharmaceuticals $LXRX Raised to “Buy” at BidaskClub https://t.co/jc1HoLRP2N May 20th 2018, 1:05pm |
|
@dispatchtribune Lexicon Pharmaceuticals $LXRX Rating Increased to Buy at BidaskClub https://t.co/wPOBPETBPH May 20th 2018, 12:05pm |
 |
@TranscriptDaily Lexicon Pharmaceuticals $LXRX Upgraded by BidaskClub to “Buy” https://t.co/7xryVzvgdP May 19th 2018, 2:05pm |
|
@ConsumerFeed Lexicon Pharmaceuticals $LXRX Receives $25.25 Average Target Price from Analysts https://t.co/BJsJ4GdFpR May 18th 2018, 8:05pm |
|
@ThisLincolnian Lexicon Pharmaceuticals $LXRX Given Consensus Recommendation of “Hold” by Brokerages https://t.co/Mu6FGeTRTr May 18th 2018, 8:05pm |
|
@ZolmaxNews Lexicon Pharmaceuticals $LXRX Upgraded to Buy at BidaskClub https://t.co/9hUpMkvgrt May 18th 2018, 2:05pm |
|
@registrarjourn Lexicon Pharmaceuticals $LXRX Upgraded to Buy at BidaskClub https://t.co/tigyVAkoPq May 18th 2018, 2:05pm |
|
@dakotafinancial Lexicon Pharmaceuticals $LXRX Lifted to “Buy” at BidaskClub https://t.co/rr6ODAVNkr May 17th 2018, 2:05am |
 |
@TheMarketsDaily Lexicon Pharmaceuticals $LXRX Lifted to “Buy” at BidaskClub https://t.co/FDOdjwBauE May 17th 2018, 2:05am |
|
@dakotafinancial Brokerages Anticipate Lexicon Pharmaceuticals $LXRX Will Announce Quarterly Sales of $22.38 Million https://t.co/yDmMKDiBgB May 16th 2018, 9:05pm |
 |
@ledgerzette Lexicon Pharmaceuticals $LXRX – Research Analysts’ Weekly Ratings Changes https://t.co/q3sHpipuiI May 16th 2018, 2:05pm |
|
@dakotafinancial Lexicon Pharmaceuticals $LXRX – Research Analysts’ Weekly Ratings Changes https://t.co/au1JN0YpLg May 16th 2018, 2:05pm |
|
@AmericanBanking Lexicon Pharmaceuticals $LXRX – Research Analysts’ Weekly Ratings Changes https://t.co/JzQ6aJWKVS #stocks May 16th 2018, 2:05pm |
|
@TheMarketsDaily Lexicon Pharmaceuticals $LXRX – Research Analysts’ Weekly Ratings Changes https://t.co/c3wwiHXUeZ May 16th 2018, 2:05pm |
|
@dispatchtribune Brokerages Set Lexicon Pharmaceuticals $LXRX Target Price at $25.25 https://t.co/M8fQAjV1lu May 16th 2018, 11:05am |
 |
@WeekHerald Lexicon Pharmaceuticals $LXRX Receives $25.25 Consensus Price Target from Analysts https://t.co/0J0KoQZVrl May 16th 2018, 11:05am |
|
@ZolmaxNews Brokerages Anticipate Lexicon Pharmaceuticals $LXRX Will Announce Earnings of -$0.42 Per Share https://t.co/v8mi1FJWnX May 14th 2018, 8:05pm |
|
@WatchlistN Zacks: Brokerages Expect Lexicon Pharmaceuticals $LXRX to Announce -$0.42 Earnings Per Share https://t.co/jN0NNlRGO0 May 14th 2018, 8:05pm |
Contact © thinkBiotech LLC 2004 - 2018. All rights reserved.